Nuvalent, Inc. (NASDAQ:NUVL) Short Interest Down 23.2% in November
Nuvalent, Inc. (NASDAQ:NUVL) Short Interest Down 23.2% in November
Nuvalent, Inc. (NASDAQ:NUVL – Get Rating) was the recipient of a large decrease in short interest in November. As of November 15th, there was short interest totalling 2,550,000 shares, a decrease of 23.2% from the October 31st total of 3,320,000 shares. Based on an average daily volume of 340,400 shares, the short-interest ratio is presently 7.5 days. Currently, 6.0% of the shares of the company are short sold.
新價公司(納斯達克：NUVL-GET Rating)是11月份空頭股數價格大幅下降的接受者。截至11月15日，空頭股數共有255萬股，比10月31日的332萬股減少了23.2%。以日均成交量340,400股計算，目前短息比率為7.5天。目前，該公司6.0%的股份被賣空。
Nuvalent Price Performance
平價性價比
NASDAQ:NUVL traded up $1.69 on Thursday, hitting $34.57. The company had a trading volume of 14,072 shares, compared to its average volume of 314,159. The firm has a 50 day moving average of $25.43 and a two-hundred day moving average of $18.07. Nuvalent has a 52 week low of $7.09 and a 52 week high of $40.43.
納斯達克：週四，NUVL股價上漲1.69美元，至34.57美元。該公司的成交量為14,072股，而其平均成交量為314,159股。該公司的50日移動均線切入位在25.43美元，200日移動均線切入位在18.07美元。現貨價位為7.09美元，為52周低點，52周高點為40.43美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, BMO Capital Markets increased their price objective on shares of Nuvalent from $28.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, October 28th.
另外，BMO Capital Markets在10月28日(星期五)的一份研究報告中將Nuvalal的股票目標價從28.00美元上調至50.00美元，並給予該公司“買入”評級。
Insiders Place Their Bets
內部人士下注
Hedge Funds Weigh In On Nuvalent
對衝基金對Nuvalal的看法
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Nuvalent by 115.6% in the 1st quarter. Vanguard Group Inc. now owns 1,637,507 shares of the company's stock valued at $22,745,000 after acquiring an additional 877,835 shares during the period. Fairmount Funds Management LLC increased its position in Nuvalent by 46.3% in the 1st quarter. Fairmount Funds Management LLC now owns 1,338,393 shares of the company's stock valued at $18,590,000 after acquiring an additional 423,779 shares during the period. BlackRock Inc. increased its position in Nuvalent by 30.2% in the 1st quarter. BlackRock Inc. now owns 1,257,463 shares of the company's stock valued at $17,466,000 after acquiring an additional 291,821 shares during the period. Millennium Management LLC acquired a new position in Nuvalent in the 2nd quarter valued at approximately $3,523,000. Finally, Driehaus Capital Management LLC increased its position in Nuvalent by 20.9% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,402,451 shares of the company's stock valued at $19,017,000 after acquiring an additional 242,383 shares during the period. Institutional investors own 95.07% of the company's stock.
機構投資者和對衝基金最近增持或減持了該股。先鋒集團在第一季度增持了115.6%的紐瓦爾股份。先鋒集團在此期間增持了877,835股，目前持有1,637,507股該公司股票，價值22,745,000美元。Fairmount Funds Management LLC在第一季度將其在Nuvality的頭寸增加了46.3%。Fairmount Funds Management LLC在此期間額外收購了423,779股，目前擁有1,338,393股該公司的股票，價值18,590,000美元。貝萊德股份有限公司在第一季度增持了30.2%的紐瓦利股份。貝萊德股份有限公司在此期間增持了291,821股，目前持有該公司1,257,463股股票，價值17,466,000美元。千禧管理公司在第二季度收購了Nuvalal公司的一個新職位，價值約為3,523,000美元。最後，Driehaus Capital Management LLC在第二季度將其在Nuvality的頭寸增加了20.9%。Driehaus Capital Management LLC在此期間額外收購了242,383股，目前擁有1,402,451股該公司的股票，價值19,017,000美元。機構投資者持有該公司95.07%的股票。
About Nuvalent
關於努瓦萊爾
(Get Rating)
(獲取評級)
Nuvalent, Inc, a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial.
新價公司是一家臨牀階段的生物製藥公司，為癌症患者開發療法。其主要候選產品有NVL-520，這是一種腦穿透性ROS1選擇性抑制劑，用於抑制ROS1融合，這種融合表達正常的ROS1激活域，沒有任何耐藥突變，並且在存在對已批准和正在研究的ROS1抑制劑產生耐藥性的突變時仍保持活性，該藥處於I期開發中；以及NVL-655，一種腦滲透性ALK選擇性抑制劑，用於解決緊急治療耐藥性、中樞神經系統相關不良事件和腦轉移等臨牀挑戰，這些挑戰可能限制正在進行I/II期臨牀試驗的第一、第二和第三代ALK抑制劑的使用。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Nuvalent (NUVL)
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
- Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
- 免費獲取StockNews.com關於Nuvalal的研究報告(NUVL)
- 賣空者對馬倫汽車股票的看法仍然正確嗎？
- La-Z-Boy傾斜到更舒適的水平
- 蘋果會在年底前大漲嗎？
- 復甦集會是為SoFi而來的嗎？
- 放寬Covid規則會降低中國電動汽車製造商蔚來的風險嗎？
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.
接受《新價日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收最新新聞和分析師對Nuvalal及相關公司評級的每日簡要摘要。